What is Harrow?
Harrow, Inc. operates as a specialized pharmaceutical entity dedicated to the development, manufacturing, and commercialization of prescription ophthalmic products. Its market position is defined by a focused commitment to addressing critical ocular disorders, including conditions related to cataract surgery, glaucoma, dry eye, and various infections. By concentrating on the specific needs of eye-care professionals, Harrow has carved out a distinct niche in the healthcare industry, prioritizing the delivery of high-quality, branded therapeutic solutions that improve patient outcomes across the United States.
How much funding has Harrow raised?
Harrow has raised a total of $113.5M across 2 funding rounds:
Debt
$1M
Debt
$112.5M
Debt (2020): $1M with participation from PPP
Debt (2023): $112.5M led by Oaktree
Key Investors in Harrow
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, recognized for its opportunistic and risk-controlled approach to credit and equity markets.
PPP
Public-Private Partnership
What's next for Harrow?
With the recent influx of capital, Harrow is well-positioned to accelerate its commercialization efforts and potentially broaden its therapeutic pipeline. The strategic nature of this funding suggests a focus on scaling operations and enhancing market penetration for its existing suite of ocular treatments. As the company moves forward, stakeholders will likely monitor its ability to maintain its competitive edge in the ophthalmic market while navigating the evolving demands of the U.S. healthcare system. The firm's emphasis on expanding access to essential eye-care therapies remains a central pillar of its long-term growth strategy, supported by a disciplined financial framework that prioritizes sustainable value creation.
See full Harrow company page
